Document text
Principal Investigator: Sheng Cai
Organization: SLOAN-KETTERING INST CAN RESEARCH
Fiscal Year: 2024
Award: $848,075
Funding agency: National Cancer Institute
PROJECT SUMMARY
The proposed Leukemia Translational Science Center (LTSC), will generate, coordinate and lead translational
studies in leukemia within ECOG-ACRIN and within the National Clinical Trials Network (NCTN). The LTSC will
serve as the central hub for studies of the Leukemia Laboratory Committee (LLC), with the support of the
Leukemia Translational Laboratory (LTRL) and the Leukemia Tissue Bank (LTB), and a comprehensive
Leukemia Data Warehouse. The LTSC is led by R. Levine, A. Melnick, and A. Ferrando. They have developed
an extensive track record in translational research leadership and implementation of state-of-the-art correlative
studies in leukemia biology. The LTSC is further enhanced through its partnership with the MSK Centers for
Molecular Oncology and Center for Hematologic Malignancies, which provide access to high-throughput
genomics technologies, state-of-the-art genomic platforms, computational resources, and the capability to
perform extensive, CLIA-certified, clinical genomics assays. In order to maximally accelerate high quality
clinical trials based on the most important science, the LTSC will establish an interaction framework that will
attract junior and senior clinical investigators, laboratory scientists, computational biologists, biostatisticians
and others, and enable them to form synergistic research teams. The LTSC will provide pilot project funding for
cross-disciplinary teams to jump-start these projects and an extensive suite of scientific resources, including
access to patient samples and clinical/molecular data, genomic and epigenetic profiling capabilities and
analytic platforms, scientific support, and a robust, productive collaborative leukemia research community. In
this way, the LTSC will ensure that translational scientific studies are seamlessly integrated into leukemia
clinical trials to identify predictors of response/outcome, identify and test novel therapies, and develop
innovative correlative studies to assess response to anti-leukemia therapies. Through these activities, the
LTSC aims to transform the standard practice of leukemia care with the development and implementation of
personalized diagnostic methods, biomarkers and therapies.
Terms: <ACRIN><Acceleration><Acute leukemia><American College of Radiology Imaging Network><Assay><Bioassay><Biological Assay><Biological Markers><Biology><CLIA accredited><CLIA approved><CLIA certified><CLIA compliant><CLIA licensed><Caring><Center for Translational Science Activities><Chronic Leukemia><Classification><Clinic><Clinical><Clinical Investigator><Clinical Trials><Clinical Trials Design><Communities><Correlative Study><Credentialing><Data><Development><Diagnostic Method><Diagnostic Procedure><Diagnostic Technique><Disease><Disorder><ECOG><Eastern Cooperative Oncology Group><Ensure><Fostering><Funding><Genomics><Goals><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><Infrastructure><Investigators><Lab Findings><Laboratories><Laboratory Finding><Laboratory Research><Laboratory Scientists><Laboratory Study><Lead><Leadership><Malignant Hematologic Neoplasm><Malignant Hematopoietic Neoplasm><Molecular><Molecular Fingerprinting><Molecular Profiling><Monitor><National Clinical Trials Network><Outcome><Pathogenesis><Patients><Pb element><Phase><Pilot Projects><Productivity><Protocol><Protocols documentation><Relapse><Research><Research Design><Research Personnel><Research Resources><Researchers><Resistance><Resources><Risk><Sampling><Science><Study Type><System><Systematics><Technology><Testing><Therapeutic><Translating><Translational Research><Translational Science><Translations><Treatment Efficacy><bio-markers><biologic marker><biomarker><biomarker discovery><blood cancer><cancer of blood><cancer of the blood><clinical care><clinical practice><computational resources><computing resources><data warehouse><developmental><discover genes><epigenetic profiling><gene discovery><genome profiling><genomic platform><genomic profiling><heavy metal Pb><heavy metal lead><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><improved outcome><innovate><innovation><innovative><insight><intervention efficacy><leukemia><leukemia tissue bank><leukemia tissue repository><leukemia treatment><leukemic therapy><molecular oncology><molecular profile><molecular signature><new drug target><new drug treatments><new druggable target><new drugs><new marker><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutic target><new therapeutics><new therapy><new therapy approaches><new therapy target><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel biomarker><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel marker><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutic target><novel therapeutics><novel therapy><novel therapy approach><novel therapy target><personalized diagnosis><personalized diagnostics><pilot study><pre-clinical research><precise diagnostics><precision diagnostics><preclinical research><predict responsiveness><predicting response><prognostic><programs><resistance mechanism><resistant><resistant mechanism><response><risk stratification><standard of care><stratify risk><study design><synergism><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic efficacy><therapeutic stratification><therapy efficacy><translation><translation research><translational investigation><translational research center><translational sciences center><translational study><treatment stratification>